Literature DB >> 28780686

High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Ilkay Kilic Muftuoglu1, William R Freeman2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28780686     DOI： 10.1007/s00417-017-3734-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Ilkay Kilic Muftuoglu; Cheryl A Arcinue; Frank F Tsai; Mostafa Alam; Raouf Gaber; Natalia Camacho; Qisheng You; William R Freeman
Journal:  Am J Ophthalmol       Date:  2016-04-02       Impact factor: 5.258

2.  High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors:  Ilkay Kilic Muftuoglu; Frank F Tsai; Raouf Gaber; Mostafa Alam; Amit Meshi; William R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-23       Impact factor: 3.117

3.  Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.

Authors:  Glenn J Jaffe; Peter K Kaiser; Desmond Thompson; Andrea Gibson; Namrata Saroj; Robert Vitti; Alyson J Berliner; Jeffrey S Heier
Journal:  Ophthalmology       Date:  2016-06-28       Impact factor: 12.079

4.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079
  4 in total
  1 in total

1.  Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.